People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TMRW Life Sciences, Inc. | — | Other Health Care | Series D+ | $184.8M | $284.2M | 2019 |
| Angiocrine Bioscience, Inc. | — | Biotechnology | Series C | $64.2M | $12.1M | 2021 |
| View Point Medical, Inc. | — | Biotechnology | Series B | $30.0M | $32.5M | 2019 |
| RF Surgical Systems, Inc | — | Other Health Care | Series A | $14.6M | $2.4M | 2010 |
Jeffrey Port at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Port on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Josh Baltzell | 2 | 7 |
| William Blair | 2 | 2 |
| Andrew Schwab | 1 | 16 |
| ALAN MURRAY | 1 | 12 |
| Paul Finnegan | 1 | 11 |
| Marc Cohen | 1 | 6 |
| Jeff Jonas | 1 | 5 |
| JOSHUA ABRAM | 1 | 5 |
| Vinay Shah | 1 | 4 |
| Douglas Carlisle | 1 | 4 |
| Doug Carlisle | 1 | 4 |
| Gary Pace | 1 | 3 |
| David Parkinson | 1 | 3 |
| Peter Klemm | 1 | 3 |
| David Goesling | 1 | 3 |
| Melanie Goldey | 1 | 3 |
| Emily Conley | 1 | 2 |
| David L Parkinson | 1 | 1 |
| Rick Geoffrey Murdock | 1 | 1 |
| Brad Geoffrey Daniel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.